Website profile

Endpoints News

Biotech and pharma business news, with a focus on the science, people and money that drive the industry.

  • 95articles · 30d
  • 1+ day agolatest article
  • Aug 15, 2026earliest in window
  • 95%with images
  • 86avg words
articles per day
Categories
  • Health & Wellness 75
  • Medical 64
  • Health 31
  • Science & Technology 31
  • Economy, Business & Finance 27
  • Finance & Business 21
  • Business & Industrial 15
  • Science & Nature 7

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Endpoints News
endpoints.news > encoded-closes-275m-series-f-for-dravet-syndrome-drug

Encoded closes $275M Series F for Dravet syndrome drug

4+ day, 15+ hour ago   (75+ words) Endpoints News En­cod­ed clos­es $275M Se­ries F for Dravet syn­drome drug En­cod­ed Ther­a­peu­tics has tacked on $275 mil­lion in new cap­i­tal, clos­ing a Se­ries F round led…...

Google News
endpoints.news > beeline-medicines-reports-promising-phase-2-lupus-data

Beeline Medicines reports promising Phase 2 lupus data

4+ day, 22+ hour ago   (81+ words) Beeline Medicines reports promising mid-stage lupus data Endpoints News Bee­line Med­i­cines re­ports promis­ing mid-stage lu­pus da­ta The busi­ness of ad­vanc­ing shelved phar­ma as­sets con­tin­ues to reap…...

Endpoints News
endpoints.news > pharvaris-stock-jumps-on-pivotal-success-in-rare-genetic-disease

Pharvaris' stock jumps on pivotal success in rare genetic disease

5+ day, 14+ hour ago   (157+ words) Pharvaris’ stock jumps on pivotal success in rare genetic disease Endpoints News We value your privacy We use third-party cookies that help us analyze how you use this website and store your preferences. However, you can opt out of these…...

Endpoints News
endpoints.news > sandoz-unveils-plan-for-biosimilar-expansion-and-new-300m-factory-in-slovenia

Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia

5+ day, 19+ hour ago   (83+ words) Endpoints News San­doz un­veils plan for biosim­i­lar ex­pan­sion and new $300M fac­to­ry in Slove­nia LON­DON — San­doz is bet­ting big on its new­ly formed biosim­i­lar unit, as…...

Endpoints News
endpoints.news > inhibrx-plots-ox40-agonist-cancer-vaccine-studies-from-early-next-year

Inhibrx opens door to cancer vaccine combo for its OX40 agonist

5+ day, 21+ hour ago   (154+ words) Endpoints News We value your privacy We use third-party cookies that help us analyze how you use this website and store your preferences. However, you can opt out of these cookies by checking "Do Not Sell or Store My Personal…...

Endpoints News
endpoints.news > ers26-roivant-reports-phase-2-win-for-lung-disease-drug-that-it-got-from-bayer

Roivant reports Phase 2 win for lung disease drug that it got from Bayer

5+ day, 23+ hour ago   (151+ words) #ERS26: Roivant reports Phase 2 win for lung disease drug that it got from Bayer Endpoints News We value your privacy We use third-party cookies that help us analyze how you use this website and store your preferences. However, you can opt…...

Endpoints News
endpoints.news > fda-approves-astrazenecas-oral-serd-for-breast-cancer-despite-negative-adcomm-vote

FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote

6+ day, 16+ hour ago   (82+ words) Endpoints News FDA ap­proves As­traZeneca’s oral SERD for breast can­cer de­spite neg­a­tive ad­comm vote As­traZeneca clinched an FDA ac­cel­er­at­ed ap­proval for its oral SERD in cer­tain…...

Endpoints News
endpoints.news > k-health-is-eyeing-an-ipo-by-2029

K Health is eyeing an IPO by 2029

1+ week, 5+ day ago   (71+ words) Endpoints News K Health is eye­ing an IPO by 2029 K Health is gear­ing up for a fu­ture pub­lic-mar­ket de­but, CEO Al­lon Bloch said af­ter a re­cent raise. The vir­tu­al…...

Endpoints News
endpoints.news > lilly-to-buy-ted-startup-merida-biosciences-in-its-13th-acquisition-of-2026

Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026

1+ week, 6+ day ago   (49+ words) Endpoints News Lil­ly to buy TED start­up Meri­da Bio­sciences in its 13th ac­qui­si­tion of 2026 Think we're worth reading - tell Google. Confirm Endpoints as a trusted biopharma news source...

Endpoints News
endpoints.news > biohaven-strikes-795m-deal-for-commercial-partner-in-epilepsy

Biohaven strikes $795M deal for commercial partner in epilepsy

2+ week, 4+ day ago   (78+ words) Endpoints News Bio­haven strikes $795M deal for com­mer­cial part­ner in epilep­sy Bio­haven has found a com­mer­cial part­ner for its late-stage epilep­sy drug. South Ko­rea-based SK Bio­phar­ma­ceu­ti…...